Pipeline Overview

Industry Leading TCR Pipeline Targeting Solid and Hematologic Cancers

Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development.

SPEAR® T-cell therapies targeting NY-ESO, MAGE-A10, MAGE-A4 and AFP are progressing into and through clinical studies in multiple U.S. clinical sites.  In addition, we have identified over 30 intracellular target peptides preferentially expressed in cancer cells and we are currently progressing 12 through un-partnered research programs.

Pipeline

Adaptimmune is developing an industry leading TCR pipeline in solid and hematologic cancers, and has a deep pipeline of identified and proprietary targets for further TCR development.

Candidate Indication Partner Development Stage
Research Pre-IND Phase 1/2
NY-ESO TCR Synovial Sarcoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Myxoid Round Cell Liposarcoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Multiple Myeloma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Ovarian GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Melanoma GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
NSCLC GSK
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Investigator Initiated Studies GSK
NCI: Synovial Sarcoma/Myeloma Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Investigator Initiated Studies GSK
ATTACK: Esophageal Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
MAGE-A10 TCR NSCLC Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
Bladder, Melanoma, and Head and Neck cancer Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
AFP TCR Hepatocellular Cancer Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress
MAGE-A4 TCR Multiple Cancer Types Wholly Owned
Research Phase complete
Pre-IND Phase complete
Phase 1/2 Phase in progress